Clinical Trials

  • This clinical research study is for women between the ages of 35 and 42 years who are having difficulty becoming pregnant and who would like to receive treatment within an assisted reproductive technology (ART) program in order to become pregnant. The purpose of this research study is to test the safety and effectiveness of an investigation drug called FE 999049, which is a new recombinant follicle-stimulating hormone (FSH) product for ovarian stimulation in women undergoing ART.
  • The UPA Breast Study will investigate a medication called ulipristal acetate (UPA), which is currently used as an emergency contraceptive and as a treatment for fibroids. The study is designed to investigate 1) whether taking UPA daily can decrease breast cell proliferation compared to traditional combined oral contraceptive pills; and 2) whether MRI can replace biopsies in future research studies investigating breast proliferation, as substituting biopsies for MRI would make future studies easier for women to take part in. Study participation will last 4-5 months.
  • The purpose of this study is to find out if the study drug, HE4 has the potential to improve performance of biomarker CA 125 to determine recurrence of epithelial ovarian cancer before detecting the cancer clinically, surgically or through radiological scans. HE4 (Human Epididymis Protein 4) is a biomarker expressed in the normal lining of the female genital tract and breast. CA 125 is a protein found on the surface of ovarian cancer cells. Study visits will consist of 5 minute blood draws.
  • Did you have unprotected sex? Do you weigh at least 176 pounds? This clinical trial is an experimental research study using a new dose of emergency contraception or morning-after pill. You may qualify if you: Are a premenopausal, healthy woman between the ages of 18 and 40. Weigh more than 176 pounds. Have an intact uterus with at least one ovary. Have regular menstrual cycles. If you qualify, you will: Receive a free investigational emergency contraceptive pill. Comply with protocol requirements, including taking an oral medication.
  • Did you have unprotected sex? Do you weigh at least 176 pounds? This clinical trial is an experimental research study using a new dose of emergency contraception or morning-after pill. You may qualify if you: Are a premenopausal, healthy woman between the ages of 18 and 40. Weigh more than 176 pounds. Have an intact uterus with at least one ovary. Have regular menstrual cycles. If you qualify, you will: Receive a free investigational emergency contraceptive pill. Comply with protocol requirements, including taking an oral medication.
  • The purpose of this study is to evaluate how accurately cells that are collected from the fallopian tube can be categorized as benign or malignant. The MAKO 7 will be used to collect cell samples from the fallopian tube. You are being asked to participate in the study because you are a woman who is undergoing a surgery to remove your fallopian tubes and/or ovaries due to a suspicious pelvic mass. The MAKO 7 device is designed to collect cells from the fallopian tube. The MAKO 7 contains a very small balloon, which enters the fallopian tube.
  • This is a study of patients delivering at Columbia University Medical Center-Allen Hospital. The investigators will compare the change in maternal hemoglobin from postpartum day 1 to day 2 and also try to find out if there is a correlation between estimated blood loss and measured blood loss.
  • HE4 (Human Epididymis Protein 4) is a biomarker expressed in the normal lining of the female genital tract and breast. We are doing this research study to if HE4 is an indicator of treatment response during initial therapy for Primary Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancers. For this we will collect blood at specific intervals. You are being asked to take part in this study because you have been diagnosed with Primary Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer and will be receiving initial treatment for your disease.
  • The purpose of this study is to find out what effects, good or bad, cobimetinib and niraparib, given with or without atezolizumab, have on you and your cancer. In this study, you will receive either cobimetinib plus niraparib or cobimetinib plus niraparib plus atezolizumab. In addition, if you are assigned to receive cobimetinib and niraparib and your cancer progresses, you could receive atezolizumab along with cobimetinib and niraparib if your doctor believes that you may benefit from this treatment.
  • The main purpose of this study is to: Find out if the study vaccine therapies cause any side effects (unexpected or unwanted reactions) and how well they are tolerated in women with persistent HPV types 16 or 18 infection of the cervix. Find out whether your body responds (the immune response). Compare the effects (both good and bad) of the study vaccines to those of the placebo injections. Theplacebo given in this study will consist of saline (sterile salt water) and looks just like the study vaccines and is given the same way, but has no active vaccine in it.

Pages